Skip to main content
Premium Trial:

Request an Annual Quote

AnaSpec, Monogram Biosciences

Premium
AnaSpec this week released its latest series of Protease or Proteinase-Activated Receptors, or PAR, peptides. A total of 17 new PARs were launched.
 

 
Monogram Biosciences said this week that beginning July 15 its HERmark Breast Cancer Assay will be available to doctors for assessing HER2 status in patients with breast cancer.
 
The assay provides a “precise and quantitative” measurement of HER2 total protein and HER2 homodimer levels, according to the company. HERmark will be offered as a CLIA-validated assay through Monogram’s CAP-certified clinical laboratory.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.